[Dysthyroidism in the post-partum period]. 1989

P Thomas-Desrousseaux
Clinique Universitaire de Gynécologie-Obstétrique et Pathologie de la Reproduction, Pavillon Paul-Gellé, Roubaix.

Post-partum dysthyroidism are not well understood by obstetricians, but are rather frequent (5.5% of the cases); they usually are the manifestation of a lympho-plasmocytic thyroidism with auto-immune origin. They are encouraged by a genetic predisposition and sometimes by food with a high iodine content. The disease starts with a phase of early thyreotoxicosis, 1 to 3 months following delivery, then later with hypothyroidism (from the 3rd to the 9th month), associated with menstrual disorders, an amenorrhea-galactorrhea syndrome or still, the occurrence of a goiter. Most of the time, the course is favorable, even in the absence of treatment with spontaneous return to euthyroidism within a few months, although the chance of permanent hypothyroidism is however non negligible. The diagnosis is difficult, and the treatment should be the least aggressive possible: beta-blocker during the thyreo-toxicosis phase, supplemental treatment during the hypothyroidism phase. There is a risk of recurrence during subsequent pregnancies.

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011644 Puerperal Disorders Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans. Disorder, Puerperal,Disorders, Puerperal,Puerperal Disorder
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D013959 Thyroid Diseases Pathological processes involving the THYROID GLAND. Disease, Thyroid,Diseases, Thyroid,Thyroid Disease

Related Publications

P Thomas-Desrousseaux
January 1995, Annales d'endocrinologie,
P Thomas-Desrousseaux
January 1967, International journal of fertility,
P Thomas-Desrousseaux
January 1963, Annales chirurgiae et gynaecologiae Fenniae,
P Thomas-Desrousseaux
December 1979, Journal d'urologie et de nephrologie,
P Thomas-Desrousseaux
January 1995, La Revue de medecine interne,
P Thomas-Desrousseaux
November 2000, Revue neurologique,
P Thomas-Desrousseaux
June 2023, The lancet. HIV,
P Thomas-Desrousseaux
January 2016, Presse medicale (Paris, France : 1983),
P Thomas-Desrousseaux
January 1947, Comptes rendus de la Societe francaise de gynecologie,
P Thomas-Desrousseaux
January 1949, Ouest-medical,
Copied contents to your clipboard!